Company description

ENTA (Entasis Therapeutics) is a clinical-stage biopharmaceutical company that focuses on developing novel antibacterial treatments for serious multidrug-resistant infections. The company's mission is to address the growing problem of antibiotic resistance by creating innovative therapies that have the potential to improve outcomes for patients in need. ENTA's approach involves identifying and targeting important bacterial pathogens using its proprietary pathogen-specific precision antibiotic platform. This platform has enabled the company to advance multiple clinical and preclinical programs, including ETX2514SUL, a Phase 3 clinical candidate for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Additionally, ENTA has a collaboration with the U.S. Department of Defense to develop a non-natural amino acid antibacterial agent for the treatment of infections caused by multidrug-resistant Acinetobacter baumannii. The company has a strong team of experienced leaders and scientists, as well as strategic partnerships with prominent institutions and organizations in the field of infectious diseases. ENTA's dedication to tackling the global threat of antibiotic resistance and its promising pipeline make it a compelling player in the biopharmaceutical industry.